SEC Comment Letter 0000000000-24-010111 to RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC.
Date: Sept. 6, 2024 · CIK: 0001553643 · Accession: 0000000000-24-010111
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281877
Letter
September 6, 2024 Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134 Re:Relmada Therapeutics, Inc. Registration Statement on Form S-3 Filed August 30, 2024 File No. 333-281877 Dear Sergio Traversa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gregory Sichenzia, Esq.
Show Raw Text
September 6, 2024
Sergio Traversa
Chief Executive Officer
Relmada Therapeutics, Inc.
2222 Ponce de Leon Blvd., Floor 3
Coral Gables, FL 33134
Re:Relmada Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 30, 2024
File No. 333-281877
Dear Sergio Traversa:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gregory Sichenzia, Esq.